Survodutide Dosing & Protocols — Research Reference

Survodutide (BI 456906) is a synthetic dual GLP-1 / glucagon receptor agonist studied in metabolic, hepatic-steatosis (MASH), and weight-research models. Its dual mechanism produces an obligate slow titration ladder to manage tolerability.

Reconstitution for Research

Survodutide is typically supplied lyophilized in 5 mg or 10 mg vials. A 2 mL bacteriostatic-water reconstitution of a 10 mg vial yields 5 mg/mL; 10 IU at that concentration delivers 500 mcg. Refrigerate at 2–8 °C and use within the COA's documented window.

Reference Dose Ranges in Published Research

| Phase | Typical range | Notes | |---|---|---| | Titration weeks 1–4 | 0.3–0.6 mg per week | Universal slow start to manage GI tolerability | | Standard maintenance | 2.4–4.8 mg per week | Most cited research tier; high-end produces durable weight-research endpoints | | Hepatic / MASH research | 2.4–6.0 mg per week | Pushed higher for liver-fat endpoint studies |

Scheduling

Once-weekly subcutaneous injection is the established protocol. The titration ladder typically doubles the dose every 4 weeks until target maintenance is reached. Rapid up-titration produces disproportionate nausea, vomiting, and biliary-research adverse events; the slow ladder is the most-cited protocol structure.

Glucagon-Arm Considerations

Survodutide's glucagon agonism contributes additional energy expenditure and hepatic lipolysis vs pure GLP-1 agonists (semaglutide, tirzepatide's GIP arm). Research protocols using survodutide for liver-fat research specifically rely on this arm; protocols using it for pure glycaemic endpoints typically choose semaglutide or tirzepatide instead.

Quality and Identity Verification

LC-MS confirmation of molecular weight and HPLC purity ≥98% are the standard acceptance criteria. Endotoxin testing applies for parenteral animal models.

Research Use Only. All content is for laboratory research and educational reference. Compounds discussed are not intended for human or veterinary consumption.

References

1. Zimmermann T, Thomas L, Baader-Pagler T, et al. BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy. Mol Metab. 2022;66:101633.
2. Jungnik A, Arrubla Martinez J, Plum-Mörschel L, et al. Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist BI 456906. Diabetes Obes Metab. 2023;25(4):1011–1023.
3. Boland ML, Laker RC, Mather K, et al. Resolution of NASH and hepatic fibrosis by the GLP-1R/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis. Nat Metab. 2020;2(5):413–431.